Overview

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Status:
Not yet recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This is a single center, open label Phase 1 clinical trial in normal adult subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide, with single ascending doses (SAD), followed by multiple dose with doses daily for 7 days.

Phase:

Phase 1

Details

Lead Sponsor:

Hillhurst Biopharmaceuticals, Inc.

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Carbon Monoxide